Xeris Biopharma Holdings, Inc. provided earnings guidance for the year 2024. The momentum continues in 2024 as the company expects to grow total revenue in the range of $170 million to $200 million. This double-digit revenue growth, coupled with recent debt refinancing and continued disciplined cash management, will allow the company to further invest in all aspects of business.